LEO MEDINA: Open Payments
NPI 1972967875 · HOUSTON, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$673 in 26 payments from 11 companies in 2025. Trend: 2023 $116 · 2024 $518 · 2025 $673
Food & beverage: $673
| Company | Payments | Amount |
|---|---|---|
| Actelion Pharmaceuticals US, Inc. | 4 | $131 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $104 |
| BridgeBio Pharma, Inc. | 3 | $97 |
| SCPHARMACEUTICALS INC. | 4 | $79 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 3 | $77 |
| Astellas Pharma US Inc | 2 | $53 |
| CVRx, Inc. | 2 | $46 |
| Analog Devices Inc. | 1 | $26 |
| PFIZER INC. | 1 | $22 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 1 | $21 |
Products named: LIVTENCITY, Attruby, FUROSCIX, UPTRAVI, OPSUMIT, Cresemba, Barostim Neo System, JASCAYD.
Industry payments across TX — which companies pay providers there.
